Navigation Links
FDA Approves 1st Skin Patch to Combat Migraines
Date:1/21/2013

By Amanda Gardner
HealthDay Reporter

MONDAY, Jan. 21 (HealthDay News) -- A skin patch for the treatment of migraines, and the intense waves of nausea that often accompany these debilitating headaches, has been approved by the U.S. Food and Drug Administration.

Called Zecuity, the patch contains sumatriptan, one of the most widely prescribed medications for migraines.

According to Dr. Fawad Khan, a neurologist with Ochsner Neuroscience Institute in New Orleans, few drugs are approved for the treatment of acute, symptomatic migraine. To complicate matters, many migraine sufferers can also experience severe bouts of nausea and vomiting.

Another expert described the problem this way.

"I've had some patients where the nausea and vomiting was so bad they couldn't even swallow a pill," said Nancy Waltman, a nurse practitioner with the University of Nebraska Medical Center College of Nursing, Lincoln Division.

A nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.

Khan said the Zecuity patch is "simple, efficient and can deliver the exact amount of dosage with minimal variability."

The patch is attached to the upper arm or thigh, and when the patient pushes a button the drug is delivered through the skin. Zecuity, which is battery-operated, delivers 6.5 milligrams of sumatriptan over the course of about five hours and can relieve nausea, as well as reduce sensitivity to light and sound.

NuPathe Inc., which makes Zecuity, hopes to have the patch on the market later this year.

Research involving 800 patients ultimately led to the approval of Zecuity. One study found that 18 percent of patients using the patch were headache-free after two hours, compared with 9 percent of those using an inactive placebo. About half achieved a reduction in their headache after two hours, compared with 29 percent of those using the placebo.

And 84 percent of patients using the patch were relieved of their nausea, compared with 63 percent of those in the placebo group, according to a company news release.

The most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.

Patients with heart disease or who are using antidepressants known as selective serotonin reuptake inhibitors should also be careful when taking sumatriptans, said Waltman, who added that she thought the patches "are wonderful."

One concern, though, is cost, Waltman cautioned.

It's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.

In general, though, "the more options that are available to migraine headache patients, the better," Waltman said. "Migraine patients tend to be underdiagnosed and undertreated and inappropriately treated."

NuPathe CEO Armando Anido told Bloomberg News, "We anticipate the product will be available for sale in the fourth quarter of this year."

More information

The U.S. National Library of Medicine has more about migraines.

SOURCES: Fawad Khan, M.D., neurologist, Ochsner Neuroscience Institute, New Orleans; Nancy Waltman, Ph.D., nurse practitioner, University of Nebraska Medical Center College of Nursing, Lincoln Division; NuPathe Inc., news release, Jan. 17, 2013; Bloomberg News


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
2. FDA Approves New Type of Flu Vaccine
3. FDA Approves New Once-a-Day HIV Pill
4. FDA Approves Flu Vaccine for Coming Season
5. FDA Approves 2nd New Weight-Loss Drug
6. FDA Approves 1st Pill to Help Prevent HIV Infection
7. FDA Approves First New Weight-Loss Drug in More Than a Decade
8. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
9. FDA Approves Combo Shot for Meningitis, Hib in Kids
10. FDA Approves Generic Versions of Plavix
11. Measles vaccine given with a microneedle patch could boost immunization programs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves 1st Skin Patch to Combat Migraines
(Date:8/23/2017)... ... August 23, 2017 , ... Arizona Spine & ... that earned the designation of High Performing Hospitals by U.S. News & World Report ... a hospital was significantly better than the national average in a given procedure ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... that has been named to the 2017 Inc. 500|5000, an exclusive ranking of ... three-year growth rate of 139 percent, marking the twelfth year that the company ...
(Date:8/23/2017)... Nashville, Tennessee (PRWEB) , ... August 23, 2017 ... ... expand its team to support long-term strategic growth plans, announcing the hiring of ... , A certified technology consultant and seasoned sales manager, Keelan will be working ...
(Date:8/23/2017)... ... August 23, 2017 , ... A ... of Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is an ... According to the report, a wider scope of physical therapy options is showing ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... collection of unique masks and serums that perfectly fuse the beauty of naturally ... at the 2017 Indie Beauty Expo on August 23rd & 24th in New ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
(Date:7/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results for ... updated its financial outlook for fiscal 2017. ... quarter, Hill-Rom reported earnings of $0.09 per diluted share ... period. These results reflect after-tax special items, including a ... the non-cash write-down of assets associated with the planned ...
Breaking Medicine Technology: